About the Authors
- Shi-Ming Li
-
Contributed equally to this work with: Shi-Ming Li, Ru Chen
Affiliation Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing, China
- Ru Chen
-
Contributed equally to this work with: Shi-Ming Li, Ru Chen
Affiliation Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China
- Yuan Li
-
Affiliation Pfizer China, Beijing, China
- Zhi-Rong Yang
-
Affiliation Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China
- Qiu-Ju Deng
-
Affiliation Department of Genetics, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Hai Dian District, Beijing, China
- Zheng Zhong
-
Affiliation Pfizer China, Beijing, China
- Moh-Lim Ong
-
Affiliation Pfizer Global Pharmaceuticals, New York, New York, United States of America
- Si-Yan Zhan
-
* E-mail: siyan-zhan@bjmu.edu.cn
Affiliation Department of Epidemiology and Health Statistics, Peking University School of Public Health, Beijing, China
Competing Interests
This study was supported by Pfizer China, Beijing. YL, ZZ and MLO are employed by Pfizer. The Latanoprost discussed in this study is manufactured by Pfizer. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: SML RC YL ZZ SYZ. Performed the experiments: SML RC. Analyzed the data: SML RC. Contributed reagents/materials/analysis tools: SML RC YL ZZ QJD ZRY. Wrote the paper: SML RC SYZ MLO.